Characteristics of L-PRP preparations for treating achilles tendon rupture within the PATH-2 study

Research output: Contribution to journalArticlepeer-review

Standard

Characteristics of L-PRP preparations for treating achilles tendon rupture within the PATH-2 study. / Harrison, Paul; Didembourg, Marie; Wood, Alexander; Devi, Amarpreet; Dinsdale, Rob; Hazeldine, Jon; Alsousou, Joseph; Keene, David; Hulley, Philippa; Wagland, Susan; Parsons, Scott; Thompson, Jacqueline; Byrne, Christopher; Schlussel, Michael Maia; O'Connor, Heather; Dutton, Susan; Lamb, Sarah; Willett, Keith.

In: Platelets, 26.11.2020.

Research output: Contribution to journalArticlepeer-review

Harvard

Harrison, P, Didembourg, M, Wood, A, Devi, A, Dinsdale, R, Hazeldine, J, Alsousou, J, Keene, D, Hulley, P, Wagland, S, Parsons, S, Thompson, J, Byrne, C, Schlussel, MM, O'Connor, H, Dutton, S, Lamb, S & Willett, K 2020, 'Characteristics of L-PRP preparations for treating achilles tendon rupture within the PATH-2 study', Platelets. https://doi.org/10.1080/09537104.2020.1849604

APA

Harrison, P., Didembourg, M., Wood, A., Devi, A., Dinsdale, R., Hazeldine, J., Alsousou, J., Keene, D., Hulley, P., Wagland, S., Parsons, S., Thompson, J., Byrne, C., Schlussel, M. M., O'Connor, H., Dutton, S., Lamb, S., & Willett, K. (2020). Characteristics of L-PRP preparations for treating achilles tendon rupture within the PATH-2 study. Platelets. https://doi.org/10.1080/09537104.2020.1849604

Vancouver

Author

Harrison, Paul ; Didembourg, Marie ; Wood, Alexander ; Devi, Amarpreet ; Dinsdale, Rob ; Hazeldine, Jon ; Alsousou, Joseph ; Keene, David ; Hulley, Philippa ; Wagland, Susan ; Parsons, Scott ; Thompson, Jacqueline ; Byrne, Christopher ; Schlussel, Michael Maia ; O'Connor, Heather ; Dutton, Susan ; Lamb, Sarah ; Willett, Keith. / Characteristics of L-PRP preparations for treating achilles tendon rupture within the PATH-2 study. In: Platelets. 2020.

Bibtex

@article{dfeff566ccdb440a938cd730f64c73e7,
title = "Characteristics of L-PRP preparations for treating achilles tendon rupture within the PATH-2 study",
abstract = "Platelet-rich plasma (PRP) is an autologous preparation that has been claimed to improve healing and mechanobiological properties of tendons both in vitro and in vivo. In this sub-study from the PATH-2 (PRP in Achilles Tendon Healing-2) trial, we report the cellular and growth factor content and quality of the Leukocyte-rich PRP (L-PRP) (N = 103) prepared using a standardised commercial preparation method across 19 different UK centres. Baseline whole blood cell counts (red cells, leukocyte and platelets) demonstrated that the two groups were well matched. L-PRP analysis gave a mean platelet count of 852.6 x 109/L (SD 438.96), a mean leukocyte cell count of 15.13 x 109/L (SD 10.28) and a mean red blood cell count of 0.91 x 1012/L (SD 1.49). The activation status of the L-PRP gave either low or high expression levels of the degranulation marker CD62p before and after ex-vivo platelet activation respectively. TGF-β, VEGF, PDGF, IGF and FGFb mean concentrations were 131.92 ng/ml, 0.98 ng/ml, 55.34 ng/ml, 78.2 ng/ml and 111.0 pg/ml respectively with expected correlations with both platelet and leukocyte counts. While PATH-2 results demonstrated that there was no evidence L-PRP is effective for improving clinical outcomes at 24 weeks after Achilles tendon rupture, our findings support that the majority of L-PRP properties were within the method specification and performance.",
keywords = "Achilles, platelet-rich plasma, rupture, tendon",
author = "Paul Harrison and Marie Didembourg and Alexander Wood and Amarpreet Devi and Rob Dinsdale and Jon Hazeldine and Joseph Alsousou and David Keene and Philippa Hulley and Susan Wagland and Scott Parsons and Jacqueline Thompson and Christopher Byrne and Schlussel, {Michael Maia} and Heather O'Connor and Susan Dutton and Sarah Lamb and Keith Willett",
note = "Funding Information: The PATH-2 trial was funded by the Efficacy and Mechanism Evaluation program, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership (reference 12/206/30). The trial was supported by the NIHR Biomedical Research Centre, Oxford, and the NIHR Fellowship program (DJK, PDF-2016-09-056). SEL receives funding from the NIHR Collaboration for Leadership in Applied Health Research and Care Oxford at Oxford Health NHS Foundation Trust. University of Birmingham staff were funded by the Scar Free Foundation (SFF) and the NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the MRC, NHS, SFF, NIHR, or Department of Health and Social Care. The sponsor (University of Oxford) and funders monitored the study but were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.",
year = "2020",
month = nov,
day = "26",
doi = "10.1080/09537104.2020.1849604",
language = "English",
journal = "Platelets",
issn = "0953-7104",
publisher = "Taylor & Francis",

}

RIS

TY - JOUR

T1 - Characteristics of L-PRP preparations for treating achilles tendon rupture within the PATH-2 study

AU - Harrison, Paul

AU - Didembourg, Marie

AU - Wood, Alexander

AU - Devi, Amarpreet

AU - Dinsdale, Rob

AU - Hazeldine, Jon

AU - Alsousou, Joseph

AU - Keene, David

AU - Hulley, Philippa

AU - Wagland, Susan

AU - Parsons, Scott

AU - Thompson, Jacqueline

AU - Byrne, Christopher

AU - Schlussel, Michael Maia

AU - O'Connor, Heather

AU - Dutton, Susan

AU - Lamb, Sarah

AU - Willett, Keith

N1 - Funding Information: The PATH-2 trial was funded by the Efficacy and Mechanism Evaluation program, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership (reference 12/206/30). The trial was supported by the NIHR Biomedical Research Centre, Oxford, and the NIHR Fellowship program (DJK, PDF-2016-09-056). SEL receives funding from the NIHR Collaboration for Leadership in Applied Health Research and Care Oxford at Oxford Health NHS Foundation Trust. University of Birmingham staff were funded by the Scar Free Foundation (SFF) and the NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the MRC, NHS, SFF, NIHR, or Department of Health and Social Care. The sponsor (University of Oxford) and funders monitored the study but were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

PY - 2020/11/26

Y1 - 2020/11/26

N2 - Platelet-rich plasma (PRP) is an autologous preparation that has been claimed to improve healing and mechanobiological properties of tendons both in vitro and in vivo. In this sub-study from the PATH-2 (PRP in Achilles Tendon Healing-2) trial, we report the cellular and growth factor content and quality of the Leukocyte-rich PRP (L-PRP) (N = 103) prepared using a standardised commercial preparation method across 19 different UK centres. Baseline whole blood cell counts (red cells, leukocyte and platelets) demonstrated that the two groups were well matched. L-PRP analysis gave a mean platelet count of 852.6 x 109/L (SD 438.96), a mean leukocyte cell count of 15.13 x 109/L (SD 10.28) and a mean red blood cell count of 0.91 x 1012/L (SD 1.49). The activation status of the L-PRP gave either low or high expression levels of the degranulation marker CD62p before and after ex-vivo platelet activation respectively. TGF-β, VEGF, PDGF, IGF and FGFb mean concentrations were 131.92 ng/ml, 0.98 ng/ml, 55.34 ng/ml, 78.2 ng/ml and 111.0 pg/ml respectively with expected correlations with both platelet and leukocyte counts. While PATH-2 results demonstrated that there was no evidence L-PRP is effective for improving clinical outcomes at 24 weeks after Achilles tendon rupture, our findings support that the majority of L-PRP properties were within the method specification and performance.

AB - Platelet-rich plasma (PRP) is an autologous preparation that has been claimed to improve healing and mechanobiological properties of tendons both in vitro and in vivo. In this sub-study from the PATH-2 (PRP in Achilles Tendon Healing-2) trial, we report the cellular and growth factor content and quality of the Leukocyte-rich PRP (L-PRP) (N = 103) prepared using a standardised commercial preparation method across 19 different UK centres. Baseline whole blood cell counts (red cells, leukocyte and platelets) demonstrated that the two groups were well matched. L-PRP analysis gave a mean platelet count of 852.6 x 109/L (SD 438.96), a mean leukocyte cell count of 15.13 x 109/L (SD 10.28) and a mean red blood cell count of 0.91 x 1012/L (SD 1.49). The activation status of the L-PRP gave either low or high expression levels of the degranulation marker CD62p before and after ex-vivo platelet activation respectively. TGF-β, VEGF, PDGF, IGF and FGFb mean concentrations were 131.92 ng/ml, 0.98 ng/ml, 55.34 ng/ml, 78.2 ng/ml and 111.0 pg/ml respectively with expected correlations with both platelet and leukocyte counts. While PATH-2 results demonstrated that there was no evidence L-PRP is effective for improving clinical outcomes at 24 weeks after Achilles tendon rupture, our findings support that the majority of L-PRP properties were within the method specification and performance.

KW - Achilles

KW - platelet-rich plasma

KW - rupture

KW - tendon

UR - http://www.scopus.com/inward/record.url?scp=85096790668&partnerID=8YFLogxK

U2 - 10.1080/09537104.2020.1849604

DO - 10.1080/09537104.2020.1849604

M3 - Article

JO - Platelets

JF - Platelets

SN - 0953-7104

ER -